India’s Dearth of Drug R&D Investment Creates Innovation Bottleneck
This article was originally published in The Pink Sheet Daily
Venture capital investment in India in first quarter 2009 down nearly 60 percent from same period a year ago; average deal size also shrinks.
You may also be interested in...
Singapore Offers Public Funds To Bridge Valley Of Death, But Can It Last? – BioMedical Asia
SINGAPORE - There is no dearth of research programs - the trouble is capital has evaporated and risk appetite is anorexic, BioMedical Asia speakers said in Singapore March 17
Network Group BayHelix Links Life Sciences Leaders To Blaze New Trail In China – An Interview With PharmAsia News (Part 2 of 2)
BayHelix is a non-profit, invitation-only organization for ethnic Chinese leaders in the global life sciences arena. Created in the San Francisco Bay Area in 2001, BayHelix has since become a bridge linking 300-plus Chinese business, law and science professionals in the health care industry across the U.S., Canada and Greater China. Recently the chairman of BayHelix, James Zhu, managing partner of Perkins Coie's Beijing Office, and the group's two co-founders, Jonathan Wang, OrbiMed's managing director in Asia, and Steve Yang, vice president, Head of Asia R&D at Pfizer, sat down with PharmAsia News' Shanghai Bureau to talk about the founding and the future of BayHelix as well as the challenges and opportunities in China's life sciences sector.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?